ATXI (Avenue Therapeutics) OCF Yield %: -117.55 (As of Jun. 29, 2026)


ATXI Avenue Therapeutics Inc ATXI
33 GF Score
Price $0.28
! 1 Warning Sign
View Full Analysis

What is Avenue Therapeutics OCF Yield %?

Avenue Therapeutics ATXI -8.35% 33 OCF Yield % is -117.55 as of Jun. 29, 2026. GuruFocus rates ATXI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,416 Biotechnology companies, Avenue Therapeutics ranks worse than 91.95% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, Avenue Therapeutics's Trailing 12-Month Cash Flow from Operations is $-1.09 Mil, and Market Cap is $0.92 Mil. Therefore, Avenue Therapeutics's OCF Yield % for today is -117.55%.

The historical rank and industry rank for Avenue Therapeutics's OCF Yield % or its related term are showing as below:

ATXI' s OCF Yield % Range Over the Past 10 Years
Min: -463.39   Med: -109.8   Max: -49.91
Current: -117.55


During the past 11 years, the highest OCF Yield % of Avenue Therapeutics was -49.91%. The lowest was -463.39%. And the median was -109.80%.

ATXI's OCF Yield % is ranked worse than
91.95% of 1416 companies
in the Biotechnology industry
Industry Median: -8.23 vs ATXI: -117.55

Avenue Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was %.


Avenue Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Avenue Therapeutics OCF Yield % Related Terms


Avenue Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for Avenue Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avenue Therapeutics OCF Yield % Chart

Avenue Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -19.32 -136.42 -229.53 -213.99 -84.64

Avenue Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -496.65 -110.17 61.15 -157.73 -183.35

ATXI vs AGTX, CLSDQ, BZYR: OCF Yield % Comparison

For the Biotechnology subindustry, Avenue Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avenue Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where Avenue Therapeutics's OCF Yield % falls into.


ATXI
33GF Score
Avenue Therapeutics Inc ATXI
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avenue Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

Avenue Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-1.833 / 2.1657568
=-84.64%

Avenue Therapeutics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-0.438 * 4 / 0.95555
=-183.35%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -117.55 mean?
Avenue Therapeutics (ATXI) has a OCF Yield % of -117.55 as of Jun. 29, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Avenue Therapeutics and its competitors. According to the industry distribution chart, Avenue Therapeutics ranks #1302 out of 1416 companies in the Biotechnology industry, placing it in the top 91.9%.
Is Avenue Therapeutics' OCF Yield % too high?
Avenue Therapeutics' current OCF Yield % is -117.55. Based on the distribution chart, Avenue Therapeutics ranks #1302 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Avenue Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Avenue Therapeutics' OCF Yield % compare to AGTX and CLSDQ?
According to the Biotechnology industry distribution chart, Avenue Therapeutics ranks #1302 out of 1416 companies for OCF Yield %. This places Avenue Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Avenue Therapeutics and its competitors. Avenue Therapeutics's current OCF Yield % is -117.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avenue Therapeutics stock overvalued right now?
Avenue Therapeutics (ATXI) has a current OCF Yield % of -117.55. The current OCF Yield % is -117.55. Avenue Therapeutics' overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Avenue Therapeutics (ATXI), the current OCF Yield % is -117.55 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avenue Therapeutics Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
33GF Score

Get the complete analysis for ATXI

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price